Age-Related Macular Degeneration (AMD) Therapeutics Market by Type and Geography - Global Forecast 2019-2023
|発行||TechNavio (Infiniti Research Ltd.)||商品コード||886883|
|出版日||ページ情報||英文 125 Pages
|加齢性黄斑変性症（AMD）治療薬の世界市場：2019年～2023年 Age-Related Macular Degeneration (AMD) Therapeutics Market by Type and Geography - Global Forecast 2019-2023|
|出版日: 2019年06月28日||ページ情報: 英文 125 Pages||
Age-related macular degeneration (AMD) is a bilateral ocular disease that affects the central area of the retina known as the macula. Technavio's age-related macular degeneration considers sales from both wet AMD, dry AMD. Our analysis also considers the sales of AMD in Asia, Europe, North America and ROW. In 2018, the wet AMD segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the increasing use of VEGF inhibitors, which are used for the treatment of wet AMD will play a significant role in the wet AMD segment to maintain its market position. Also, our global age-related macular degeneration market report also looks at factors such as high prevalence of AMD, strong pipeline and expected approvals, and rising geriatric populations. However, lack of approved therapies for dry AMD, introduction of biosimilars, side effects of available therapeutics may hamper the growth of the age-related macular degeneration industry over the forecast period.
The prevalence of AMD is extremely high, owing to the presence of high-risk factors for developing the condition. Risk factors such as aging, smoking, high cholesterol, and high blood pressure are the major contributors to the development of AMD. Moreover, despite the high prevalence of AMD, no approved therapies are available in the market for the treatment of the condition. Thus, the high prevalence coupled with the huge unmet medical need of dry AMD is expected to drive the market at a CAGR of over 8% during the forecast period.
There is a huge unmet need for safe and novel drugs to treat AMD. The currently available anti-VEGF therapies require repetitive and inconvenient intraocular injections. Owing to factors such as inconvenience and discomfort associated with frequent injections in the eye, patient compliance is a significant concern with anti-VEGF therapies. Hence, several companies are working on novel drugs against AMD, among which gene therapy is expected to cure the disease effectively. Hence, the development of gene therapy is expected to be a positive trend for the global AMD therapeutics market.
For the detailed list of factors that will drive the global age-related macular degeneration (and) therapeutics market during the forecast period 2019-2023, view our report.
With the presence of few major players, the global age-related macular degeneration (AMD) therapeutics market is moderately concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading age-related macular degeneration manufacturers, that include Amgen Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Regeneron Pharmaceuticals Inc.
Also, the age-related macular degeneration market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.